Anti-Viral Drug Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Implications and Growth

Publish Date: Dec 2020

Report Code: TBR804B

Publisher: TBRC (Publisher)

Single User License: $4000

Explore Our Services

Already a member? Login here.

Report Highlights

Anti-Viral Drug Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Implications and Growth

Including: By Drug Class: DNA (Nucleotide) Polymerase Inhibitors; Reverse Transcriptase Inhibitors; Protease Inhibitors; Neuraminidase Inhibitors; Others
By Application: HIV; Hepatitis; Herpes; Influenza; Others

Covering: Gilead Sciences Inc.; GlaxoSmithKline plc; Johnson & Johnson; AbbVie Inc.; Merck & Co., Inc.

Anti-Viral Drug Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Implications And Growth from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global anti-viral drug therapy market.

Reasons to Purchase

  • Outperform competitors using accurate up to date demand-side dynamics information.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Identify growth segments for investment.
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
  • Create regional and country strategies on the basis of local data and analysis.
  • Stay abreast of the latest customer and market research findings
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future developments.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Gain a global perspective on the development of the market.

Description:
Where is the largest and fastest growing market for the anti-viral drug therapy market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global anti-viral drug therapy market opportunities and strategies to 2030 report from the Business Research Company answers all these questions and many more.

The report covers the following chapters

Executive Summary – The executive summary section of the report gives a brief overview and summary of the report

Report Structure – This section gives the structure of the report and the information covered in the various sections.

Introduction – The introduction section of the report gives brief introduction about segmentation by geography, segmentation by drug class, by application.

Market Characteristics – The market characteristics section of the report defines and explains the anti-viral drug therapy market. This chapter also defines and describes goods and related services covered in the report.

Trends And Strategies – This chapter describes the major trends shaping the global anti-viral drug therapy market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.

Impact of COVID-19 – This section describes the impact of COVID-19 on the anti-viral drug therapy market.
Global Market Size And Growth – This section contains the global historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods. 

Regional Analysis – This section contains the historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values and growth and market share comparison by region.

Segmentation – This section contains the market values (2015-2030) and analysis for different segments.

Regional Market Size and Growth – This section contains the region’s market size (2019), historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.

Competitive Landscape – This section covers details on the competitive landscape of the global anti-viral drug therapy market, estimated market shares and company profiles for the leading players.

Key Mergers And Acquisitions – This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.

Future Outlook and Potential Analysis – This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.

Conclusions And Recommendations – This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for anti-viral drug therapy companies in terms of product offerings, geographic expansion, marketing strategies and target groups.

Appendix – This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report

Markets Covered:

The global anti-viral drug therapy market is segmented into -
By Drug Class: DNA (Nucleotide) Polymerase Inhibitors; Reverse Transcriptase Inhibitors; Protease Inhibitors; Neuraminidase Inhibitors; Others 
By Application: HIV; Hepatitis; Herpes; Influenza; Others

Companies Mentioned: Gilead Sciences Inc.; GlaxoSmithKline plc; Johnson & Johnson; AbbVie Inc.; Merck & Co., Inc.

Countries: China, Japan, India, Australia, Indonesia, South Korea, USA, Brazil, UK, Germany, France, Russia

Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

  • Table 1 : Global Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 2 : Global Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 3 : Global Anti-Viral Drug Therapy Market, By Region, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Table 4 : Global Anti-Viral Drug Therapy Market, By Region, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, $ Million
  • Table 5 : Global Anti-Viral Drug Therapy Market, By Country, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Table 6 : Global Anti-Viral Drug Therapy Market, By Country, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7 : Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Table 8 : Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, $Million
  • Table 9 : Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,%
  • Table 10 : Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,$ Million
  • Table 11 : Asia Pacific Population By Age Group, 2015-2023, Thousands
  • Table 12 : Asia-Pacific Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 13 : Asia Pacific GDP Per Capita, 2015-2019, $
  • Table 14 : Asia Pacific HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 15 : Asia Pacific Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 16 : Asia Pacific Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 17 : Asia Pacific Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 18 : Asia-Pacific Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 19 : Asia-Pacific Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 20 : Asia-Pacific Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,%
  • Table 21 : Asia-Pacific Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,$Million
  • Table 22 : China Population By Age Group, 2015-2023, Thousands
  • Table 23 : China Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 24 : China GDP Per Capita, 2015-2019, $
  • Table 25 : China HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 26 : China Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 27 : China Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 28 : China Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 29 : China Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 30 : China Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 31 : China Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Table 32 : China Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, $ Million
  • Table 33 : Australia Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 34 : Australia Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 35 : Australia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,%
  • Table 36 : Australia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, $ Million
  • Table 37 : India Population By Age Group, 2015-2023, Thousands
  • Table 38 : India Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 39 : India GDP Per Capita, 2015-2019, $
  • Table 40 : India HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 41 : India Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 42 : India Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 43 : India Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 44 : India Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 45 : India Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 46 : India Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Table 47 : India Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, $Million
  • Table 48 : Indonesia Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 49 : Indonesia Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 50 : Indonesia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F<%
  • Table 51 : Indonesia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F<$ Million
  • Table 52 : Japan Population By Age Group, 2015-2023, Thousands
  • Table 53 : Japan Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 54 : Japan GDP Per Capita, 2015-2019, $
  • Table 55 : Japan HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 56 : Japan Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 57 : Japan Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 58 : Japan Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 59 : Japan Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 60 : Japan Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 61 : Japan Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Table 62 : Japan Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, $ Million
  • Table 63 : South Korea Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 64 : South Korea Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 65 : South Korea Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,%
  • Table 66 : South Korea Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, $Million
  • Table 67 : Western Europe Population By Age Group, 2015-2023, Thousands
  • Table 68 : Western Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 69 : Western Europe GDP Per Capita, 2015-2019, $
  • Table 70 : Western Europe HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 71 : Western Europe Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 72 : Western Europe Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 73 : Western Europe Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 74 : Western Europe Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 75 : Western Europe Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 76 : Western Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F,230F<%
  • Table 77 : Western Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F,2030F, $Million
  • Table 78 : UK Population By Age Group, 2015-2023, Thousands
  • Table 79 : UK Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 80 : UK GDP Per Capita, 2015-2019, $
  • Table 81 : UK HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 82 : UK Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 83 : UK Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 84 : UK Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 85 : UK anti-viral drug therapy market, Historic, 2015 - 2019, $ Million
  • Table 86 : UK Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 87 : UK Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Table 88 : UK Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, $ Million
  • Table 89 : France Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 90 : France Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 91 : France Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,%
  • Table 92 : France Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,$ million
  • Table 93 : Germany Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 94 : Germany Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 95 : Germany Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,%
  • Table 96 : Germany Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,$ Million
  • Table 97 : Eastern Europe Population By Age Group, 2015-2023, Thousands
  • Table 98 : Eastern Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 99 : Eastern Europe GDP Per Capita, 2015-2019, $
  • Table 100 : Eastern Europe HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 101 : Eastern Europe Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 102 : Eastern Europe Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 103 : Eastern Europe Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 104 : Eastern Europe Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 105 : Eastern Europe Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 106 : Eastern Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F,2030F, %
  • Table 107 : Eastern Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F,2030F,$ Million
  • Table 108 : Russia Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 109 : Russia Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 110 : Russia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,%
  • Table 111 : Russia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,$ Million
  • Table 112 : North America Population By Age Group, 2015-2023, Thousands
  • Table 113 : North America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 114 : North America GDP Per Capita, 2015-2019, $
  • Table 115 : North America HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 116 : North America Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 117 : North America Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 118 : North America Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 119 : North America Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 120 : North America Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 121 : North America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F,2030F, %
  • Table 122 : North America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F,2030F, $Million
  • Table 123 : USA Respiratory Masks (N95 Respirators, Surgical Masks, And Others) Market, Population By Age Group, 2015-2023, Thousands
  • Table 124 : USA Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 125 : USA GDP Per Capita, 2015-2019, $
  • Table 126 : USA HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 127 : USA Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 128 : USA Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 129 : USA Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 130 : USA Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 131 : USA Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 132 : USA Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Table 133 : USA Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, $Million
  • Table 134 : South America Population By Age Group, 2015-2023, Thousands
  • Table 135 : South America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 136 : South America GDP Per Capita, 2015-2019, $
  • Table 137 : South America HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 138 : South America Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 139 : South America Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 140 : South America Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 141 : South America Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 142 : South America Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 143 : South America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,%
  • Table 144 : South America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F,2030F, $Million
  • Table 145 : Brazil Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 146 : Brazil Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 147 : Brazil Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,%
  • Table 148 : Brazil Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,$ Million
  • Table 149 : Middle East Population By Age Group, 2015-2023, Thousands
  • Table 150 : Middle East Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 151 : Middle East GDP Per Capita, 2015-2019, $
  • Table 152 : Middle East HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 153 : Middle East Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 154 : Middle East Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 155 : Middle East Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 156 : Middle East Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,%
  • Table 157 : Middle East Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, $ Million
  • Table 158 : Africa Population By Age Group, 2015-2023, Thousands
  • Table 159 : Africa Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 160 : Africa GDP Per Capita, 2015-2019, $
  • Table 161 : Africa HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 162 : Africa Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 163 : Africa Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Table 164 : Africa Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Table 165 : Africa Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,%
  • Table 166 : Africa Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F,$ Million
  • Table 167 : Global Anti-Viral Drug Therapy Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Table 168 : Gilead Sciences Inc - Financial Performance, 2015 - 2019, $ Billion
  • Table 169 : GlaxoSmithKline plc - Financial Performance, 2015 - 2019, $ Billion
  • Table 170 : Johnson & Johnson (J&J) - Financial Performance, 2015 - 2019, $ Billion
  • Table 171 : AbbVie Inc - Financial Performance, 2015 - 2019, $ Billion
  • Table 172 : Merck & Co. - Financial Performance, 2015-2019, $ Billion
  • Table 173 : Global Anti-Viral Drug Therapy Market Size Gain ($ Million), 2019 - 2023, By Country
  • Table 174 : Global Anti-Viral Drug Therapy Market Size Gain ($ Million), Segmentation By Drug Class, 2019 - 2023
  • Table 175 : Global Anti-Viral Drug Therapy Market Size Gain ($ Million), Segmentation By Application, 2019 - 2023
  • Table 176 : Anti- Viral Drug Therapy- Market Data Sources
  • Figure 1 : Global Anti-Viral Drug Therapy Market Segmentation By Drug Class
  • Figure 2 : Global Anti-Viral Drug Therapy Market Segmentation By Application
  • Figure 3 : Global Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 4 : Global Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 5 : Global Anti-Viral Drug Therapy Market, By Region, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 6 : Global Anti-Viral Drug Therapy Market, By Country, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 7 : Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 8 : Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 9 : Asia-Pacific Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 10 : Asia-Pacific Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 11 : Asia-Pacific Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 12 : China Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 13 : China Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 14 : China Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 15 : Australia Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 16 : Australia Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 17 : Australia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 18 : India Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 19 : India Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 20 : India Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 21 : Indonesia Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 22 : Indonesia Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 23 : Indonesia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 24 : Japan Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 25 : Japan Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 26 : Japan Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 27 : South Korea Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 28 : South Korea Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 29 : South Korea Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 30 : Western Europe Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 31 : Western Europe Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 32 : Western Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 33 : UK Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 34 : UK Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 35 : UK Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 36 : France Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 37 : France Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 38 : France Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 39 : Germany Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 40 : Germany Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 41 : Germany Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 42 : Eastern Europe Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 43 : Eastern Europe Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 44 : Eastern Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 45 : Russia Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 46 : Russia Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 47 : Russia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 48 : North America Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 49 : North America Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 50 : North America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 51 : USA Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 52 : USA Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 53 : USA Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 54 : South America Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 55 : South America Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 56 : South America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 57 : Brazil Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 58 : Brazil Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 59 : Brazil Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 60 : Middle East Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 61 : Middle East Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 62 : Middle East Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 63 : Africa Anti-Viral Drug Therapy Market, Historic, 2015 - 2019, $ Million
  • Figure 64 : Africa Anti-Viral Drug Therapy Market, Forecast, 2019 - 2023, 2025F, 2030F, $ Million
  • Figure 65 : Africa Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, %
  • Figure 66 : Global Anti-Viral Drug Therapy Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Figure 67 : Gilead Sciences Inc - Financial Performance, 2015 - 2019, $ Billion
  • Figure 68 : GlaxoSmithKline plc - Financial Performance, 2015 - 2019, $ Billion
  • Figure 69 : Johnson & Johnson (J&J) - Financial Performance, 2015 - 2019, $ Billion
  • Figure 70 : AbbVie Inc - Financial Performance, 2015 - 2019, $ Billion
  • Figure 71 : Merck & Co. - Financial Performance, 2015-2019, $ Billion

The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Similar Reports from TBRC (Publisher)

Anti-Viral Drug Therapy Global Market Report 2020-30: Covid 19 Implications and Growth

  • Date - Apr 2020
  • Code - TBR804A

Including: 1) By Drug Class: DNA Polymerase Inhibitors; Reverse Transcriptase Inhibitors; Protease Inhibitors; Neuraminidase Inhibitors; Others; 2) By Application: HIV; Hepatitis; Herpes; Influenza; Others

Covering: AbbVie Inc.; Bristol-Myers-Squibb; Cipla; F. Hoffmann-La Roche Ltd; Gilead Sciences Inc

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Anti-Viral Drug Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Implications and Growth